evipedia.ai
← Back

Thymalin for Health & Longevity

Evidence Review created on 08/31/2026 using AI4L / Opus 5

Also known as: Timalin, Tymalin, Thymalinum, Calf Thymus Polypeptide Extract, Thymus Peptide Bioregulator

Motivation

Thymalin is a mixture of small protein fragments extracted from the thymus glands of young calves. The thymus is the small gland behind the breastbone where developing immune cells learn to tell the body’s own tissues from invaders. It shrinks steadily from adolescence onward, and much of the weakening of immune defence in later life tracks that shrinkage. Thymalin was built on the idea that returning thymus-derived signals to an older body might restore part of what is lost.

It has been a registered injectable medicine in Russia and neighbouring countries for more than four decades, given to help the immune system recover after burns, surgery, severe infection and radiation exposure. Long-term follow-up of older adults reported fewer respiratory illnesses and longer survival — a claim never tested outside the region where the compound was developed.

This review examines what the published record does and does not establish: how Thymalin is thought to act, which benefits and harms have been recorded, how it has been dosed, how it can be obtained, and what would need to be measured to tell whether it is doing anything.

Benefits - Risks - Protocol - Conclusion

High-level sources that put Thymalin, and the thymic peptide class it belongs to, in context for a non-specialist.

  • Thymic involution - FoundMyFitness

    Sets out the deficit Thymalin is proposed to correct: the age-related shrinkage of the thymus, the falling T-cell output that follows, and the diet, weight and stress factors that alter its pace.

  • Benefits & Risks of Peptide Therapeutics for Physical & Mental Health - Andrew Huberman

    A long-form treatment of the injectable peptide category, including thymosin beta-4 and its truncated form TB-500 — thymus-derived peptides — and of the regulatory position that keeps such compounds off the licensed market.

  • When Immune Function “Falls Off a Cliff” - William Faloon

    Explains the deficit Thymalin targets — the collapse in naive T-cell output that follows thymic shrinkage after about age 65 — and surveys the non-peptide agents proposed to counter it.

  • Can you reverse your biological age? - Peter Attia

    Walks through the thymus-regeneration trial that defines the target Thymalin claims: reversing thymic involution to restore T-cell output, and how to judge such a study’s evidence.

  • The Thymus Hormone Thymulin Reduces Inflammaging in Mice - Anna Drangowska-Way

    A thymus-derived peptide hormone, thymulin, lowered age-related inflammatory signalling in old mice — the same thymic-peptide route Thymalin is proposed to act through, tested in a controlled animal model.

No relevant content was found from Chris Kresser. Direct site searches and web searches returned nothing on Thymalin, on thymic peptide bioregulators, or on thymic involution; the topic sits outside his published coverage.

Grokipedia

No Grokipedia article on Thymalin exists as of 31 August 2026.

Examine

No Examine article on Thymalin exists as of 31 August 2026.

Thymalin is a registered prescription injectable in its countries of origin, not a dietary supplement, and Examine does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article or product review on Thymalin exists as of 31 August 2026.

ConsumerLab tests retail dietary supplements; Thymalin is a prescription injectable outside that scope, and ConsumerLab does not typically cover prescription medications.

Systematic Reviews

Systematic reviews and meta-analyses covering the thymic peptide class to which Thymalin belongs, since none exists for the compound itself.

No systematic reviews or meta-analyses for Thymalin were found on PubMed as of 31 August 2026. The five below evaluate purified thymus extracts and synthetic thymic peptides — the class Thymalin sits in — and are the closest available synthesis. On the trade-off: pooled evidence exists for the claimed benefit (survival, infection, tumour response) and for the principal harm (tolerability and adverse events), but no pooled analysis addresses the long-term mortality claim specific to Thymalin, which remains unrepresented in the systematic review literature.

Mechanism of Action

Thymalin is not a single molecule but an acid extract of calf thymus: polypeptides below roughly 10 kilodaltons plus two short dipeptides — glutamyl-tryptophan and lysyl-glutamate — later isolated and marketed separately.

The proposed primary action is restoring production of T-lymphocytes (white blood cells that direct immune defence). In cultured human hematopoietic stem cells (immature cells that generate all blood cells), Thymalin cut the immature markers CD44 and CD117 two- to threefold and raised CD28, a surface protein carried by mature T-lymphocytes, 6.8-fold — consistent with driving precursors toward finished T cells.

A second action is damping inflammatory signalling. In stimulated human blood immune cells, Thymalin and its two dipeptides cut release of interleukin-1β, interleukin-6 and tumour necrosis factor alpha — proteins that drive fever and tissue inflammation — by 1.4- to 6-fold. Molecular modelling places the dipeptides at specific DNA sequences in gene promoter regions, putting the effect at the level of gene transcription. Both mechanistic studies are from the compound’s developers.

The competing account is that an undefined tissue hydrolysate acts as a non-specific immune stimulus rather than a targeted regulator, and that the clinical effects owe more to unconcealed allocation than to the peptides.

Formal pharmacokinetics have never been published. The mixture is destroyed by digestive enzymes, so it is injected; its constituents are hydrolysed to free amino acids within minutes, are not handled by cytochrome P450 enzymes (the liver’s main drug-processing system), and have no documented receptor selectivity or tissue distribution beyond lymphoid tissue.

Historical Context & Evolution

Thymalin came out of the Kirov Military Medical Academy in Leningrad, where between 1971 and 1974 Vyacheslav Morozov and Vladimir Khavinson developed a mild acid extraction of low-molecular-weight peptides from calf thymus. The original purpose was military and surgical: correcting the immune collapse following severe burns, trauma, radiation exposure and post-operative sepsis. The USSR Ministry of Health registered it in 1982, and it entered routine hospital use, including for radiation-induced immune deficiency after Chernobyl.

The longevity claim came second. Animal work at the Petrov Institute of Oncology reported that peptide preparations of this class extended mean rodent lifespan by 20–40% and suppressed spontaneous and induced tumours. That led to the 6–8 year clinical programme in 266 people over 60 in St. Petersburg and Kiev, which reported lower mortality and less age-related disease. Both strands came from the St. Petersburg Institute of Bioregulation and Gerontology, which developed the compound and derives revenue from the peptide line built on it.

Western medicine did not so much test these findings as bypass them. Effort went to defined single molecules — thymosin alpha-1, thymopentin — which are patentable and characterisable for a regulatory dossier. An unpatentable calf-tissue extract has no commercial sponsor and no institutional payer with an incentive to fund a trial, so the absence of replication reflects funding structure as much as any weighing of evidence. The Cochrane review of related preparations found no survival benefit but fewer severe infections — a mixed result that neither confirms nor overturns the Russian claims.

Expected Benefits

High 🟩 🟩 🟩

Faster Recovery from Severe Acute Respiratory Infection

Adding Thymalin to standard hospital care for severe COVID-19 (the illness caused by the SARS-CoV-2 coronavirus) shortened the inflammatory phase and, in one dataset, was followed by fewer deaths. The proposed mechanism is restored T-cell numbers plus suppression of the cytokine surge that drives lung injury. Evidence is one randomised controlled trial of 92 hospitalised patients, in which no patient in either arm died, and one non-randomised comparative study that supplies the entire mortality signal. Both were open-label and run by investigator groups tied to the developing institute.

Magnitude: In the non-randomised comparison, hospital mortality in severe disease was 20.6% with Thymalin versus 40.9% with standard care alone; in the randomised trial, which recorded no deaths in either arm, radiographic progression occurred in 2 of 42 treated patients versus 5 of 50 controls, lymphocyte counts rose 55%, and interleukin-6 fell 5.5-fold.

Medium 🟩 🟩

Repeated annual courses in people over 60 were followed by lower death rates and less new cardiovascular, joint and bone disease over 6–8 years. The proposed mechanism is partial reversal of age-related T-cell decline and the chronic inflammation that accompanies it. The evidence is a single controlled but unblinded cohort of 266 people, conducted and reported by the institute that developed and sells the compound, and never replicated by an independent group. That combination caps the grade at Medium regardless of the size of the reported effect.

Magnitude: Mortality over the observation period fell 2.0- to 2.1-fold versus control with Thymalin alone, and 4.1-fold in the subgroup given Thymalin plus a pineal peptide annually for six years; acute respiratory illness incidence fell 2.0- to 2.4-fold.

Low 🟩

Faster Wound Closure and Shorter Hospital Stay After Severe Burns

In a 32-patient comparative series with third- and fourth-degree burns, Thymalin resolved disseminated intravascular coagulation (widespread small-vessel clotting that consumes clotting factors), normalised clot breakdown and shifted the balance of inflammatory and anti-inflammatory cytokines. The series was small, unblinded and single-centre.

Magnitude: The first skin graft was performed about 5 days earlier and hospital stay was about 11 days shorter than in comparison patients.

Faster Resolution of Acute Suppurative and Post-Surgical Infection

Soviet-era hospital series added Thymalin to standard care in suppurative (pus-forming) conditions — erysipelas (a skin infection), traumatic osteomyelitis of the lower jaw (bone infection) and critical trauma — reporting faster clearance and normalised immune indices. These were the compound’s original registered indications. All were unblinded, single-centre and largely uncontrolled.

Magnitude: Reports describe faster clearance of suppurative foci and fewer infectious complications than standard care alone, with the effect largest in patients entering with depressed T-cell counts; the literature reports no pooled effect size for any of these indications.

Recovery of Immune Indices After Radiation or Cancer Treatment ⚠️ Conflicted

Thymalin corrected radiation-induced immunodeficiency in 100 patients after Chernobyl and improved cell-mediated immunity in 35 of 111 endometrial cancer patients on hormone therapy — both uncontrolled records. Clinical outcomes did not follow: the Cochrane review found no survival or tumour-response gain. Net reading: immune markers move, clinical outcomes do not.

Magnitude: Lymphocyte and T-cell subset counts are reported to move toward reference ranges over a course, with the effect confined to those actually immunosuppressed; across the wider class, severe infectious complications fell (risk ratio 0.54, 95% confidence interval 0.38 to 0.78 — a 46% relative reduction, with the interval showing a true effect between 22% and 62%), with no survival gain.

Shorter Hospital Stay in Destructive Pulmonary Tuberculosis

A 60-patient clinical trial added Thymalin to standard chemotherapy on the basis of pre-treatment immune testing, reporting shorter admissions, better treatment efficacy and normalisation of immune indices. Allocation was by immune profile rather than randomisation.

Magnitude: Hospital stay was shortened and treatment efficacy increased relative to chemotherapy alone; the report gives direction only and states no numerical effect size.

Speculative 🟨

Reduced Spontaneous Tumour Formation

Rodent carcinogenesis experiments reported suppression of spontaneous and chemically induced tumours with repeated thymus preparation courses. No human cancer-incidence data exist; the basis is animal work only.

Restoration of Blood Stem-Cell Differentiation Toward Mature T Cells

Cultured human blood-forming stem cells shifted from immature toward mature T-cell markers on exposure to Thymalin. This is an in-vitro marker assay with no human outcome attached, so it caps here.

Slowed Development of Experimental Atherosclerosis

Animal work reported that Thymalin slowed experimentally induced hyperlipidaemia and arterial plaque formation. The basis is animal models only; no human lipid or cardiovascular endpoint has been measured.

Benefit-Modifying Factors

  • Genetic polymorphisms: None validated. FOXN1, the transcription factor that maintains thymic epithelial tissue, and human leukocyte antigen type, the genes that set immune self-recognition, both plausibly cap how much T-cell output can be recovered, but no study has genotyped Thymalin recipients.
  • Baseline biomarker levels: The largest changes occurred in people starting with lymphopenia (an abnormally low lymphocyte count) and raised interleukin-6. Those entering with normal counts and low inflammation have little measured headroom for improvement.
  • Sex-based differences: Not reported. Women retain thymic tissue slightly longer than men and mount stronger T-cell responses, which would predict a smaller relative gain, but no trial has analysed Thymalin results by sex.
  • Pre-existing health conditions: Acute infection, extensive burns and post-surgical immune suppression are the states in which effects were largest. Stable, well-compensated chronic health is where evidence for any effect is thinnest.
  • Age: Thymic output falls by roughly 95% between age 20 and 70, so the deficit this compound targets barely exists in younger adults. Every positive human dataset comes from people over 60 or acutely ill patients.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome of Thymalin has been quantified in more than one controlled trial, the published trials report efficacy endpoints and describe tolerability only narratively, and no post-marketing pharmacovigilance dataset has been published despite four decades of registered use.

Medium 🟥 🟥

Hypersensitivity and Injection-Site Reactions

Thymalin is a foreign bovine protein mixture injected into muscle, and the product information lists allergic reactions — rash, redness and itching at the injection site — as the adverse effect category, with hypersensitivity as the principal contraindication. The evidence class is consistent post-marketing observation across four decades of registered use, supported by the finding that tolerability of purified thymus extracts was good across 26 randomised trials. Reactions are mild and local; systemic anaphylaxis is undocumented but cannot be excluded for any injected foreign protein.

Magnitude: Reactions are confined to rash, redness and itching at or near the injection site, become more likely with repeated courses and in people with existing allergic disease, and the literature reports no incidence figure — neither the product information nor any published trial states a rate.

Low 🟥

Amplified Allergic Reactions to Co-Administered Drugs

The product information warns that Thymalin can potentiate allergic reactions to drugs given concurrently, a warning traceable to Soviet-era use including administration in patients with an allergic history. The proposed mechanism is non-specific immune priming lowering the reaction threshold to a co-administered antigen. Human data are uncontrolled.

Magnitude: Not quantified in available studies. The warning rests on manufacturer post-marketing observation; no controlled trial has co-administered Thymalin with a known allergen and measured reaction rates.

Worsening of Autoimmune Disease ⚠️ Conflicted

Stimulating T-cell production where T cells already attack self tissue is mechanistically hazardous, and the product information lists autoimmune disease as a contraindication. Yet the small uncontrolled Soviet-era reports in multiple sclerosis and rheumatoid arthritis recommend Thymalin rather than record flares. Net reading: the hazard is unresolved, not demonstrated.

Magnitude: Not quantified in available studies. The only human autoimmune exposures recorded improvement rather than flares, so no flare rate exists in the literature to report.

Speculative 🟨

Transmissible Agent from Bovine Source Material

The starting material is calf thymus, a lymphoid tissue. No prion or viral transmission from Thymalin has ever been reported; the concern is theoretical, resting on tissue origin rather than human outcome data.

Contaminated or Misidentified Grey-Market Product

Vials bought outside the registered supply chain carry unverified identity, sterility and endotoxin status. No human harm from grey-market Thymalin has been documented, so the concern rests on the general behaviour of unregulated injectables.

Acceleration of an Occult Lymphoid Malignancy

Thymalin drives lymphocyte proliferation and has been given in chronic lymphocytic leukaemia. Whether it could accelerate an undiagnosed lymphoid clone is untested; no human outcome data address the question.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. Human leukocyte antigen type, which sets the threshold for immune self-recognition, plausibly governs who reacts adversely to immune stimulation, but this has never been tested for Thymalin.
  • Baseline biomarker levels: A positive antinuclear antibody result or raised thyroid peroxidase antibodies marks latent autoimmunity; a high total immunoglobulin E marks the allergic constitution the product information singles out for extra caution.
  • Sex-based differences: No sex-stratified safety data exist. Autoimmune thyroid and connective-tissue disease is several times more common in women, so the theoretical autoimmune hazard of immune stimulation falls disproportionately on them.
  • Pre-existing health conditions: Active autoimmune disease, solid-organ transplant on immunosuppression, lymphoid malignancy and known bovine protein allergy convert a low-risk injection into a plausible hazard.
  • Age: Older adults are both the target group and the group carrying the most undiagnosed monoclonal and autoimmune conditions, so the value of screening before a first course rises sharply past age 70.

Key Interactions & Contraindications

Prescription medications:

  • Transplant immunosuppressants (tacrolimus, ciclosporin, mycophenolate, sirolimus): Absolute contraindication. Direct pharmacodynamic antagonism — T-cell stimulation opposes the entire purpose of the drug. Clinical consequence is graft rejection. No dose adjustment makes the combination acceptable.
  • Systemic corticosteroids (prednisone, dexamethasone, methylprednisolone): Caution. Glucocorticoids drive thymic shrinkage and suppress T-cell function, so any Thymalin effect is likely abolished; the consequence is wasted exposure rather than harm. Published courses begin at least four weeks after steroid withdrawal.
  • Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab): Absolute contraindication during treatment. Additive immune activation; consequence is severe immune-related adverse events such as colitis, hepatitis or pneumonitis. No monitoring schedule makes concurrent use acceptable.
  • Anticoagulants and antiplatelets (warfarin, apixaban, aspirin, enoxaparin): Monitor. Thymalin lowered fibrinogen and enhanced clot breakdown in published trials; consequence is a possible additive bleeding tendency. Fibrinogen and a clotting screen after a first course track this.
  • Biologic disease-modifying drugs (adalimumab, rituximab, tocilizumab): Caution. Opposing pharmacology in autoimmune disease; consequence is loss of disease control. Courses are best confined to periods off biologic therapy rather than overlapped with it.

Over-the-counter medications:

  • Oral antihistamines (cetirizine, loratadine): Caution. No metabolic interaction, but pre-medicating masks an early hypersensitivity reaction. Consequence is delayed recognition rather than direct harm; routine pre-dosing obscures reactions that would otherwise stay visible.
  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen): Monitor. Both lower the inflammatory markers used to judge response, so combining them confounds interleukin-6 and C-reactive protein readings. Consequence is uninterpretable monitoring; a 72-hour gap before testing preserves the reading.

Supplements:

  • Immunostimulant supplements (echinacea, AHCC, beta-glucans, Trametes versicolor extract): Caution — additive immune activation. Consequence is amplified immune symptoms and inability to attribute a reaction to one agent; practice is to withhold them during and for one week after a course.
  • Zinc and dehydroepiandrosterone: Additive in the intended direction — both partially restore thymic function. Consequence is a larger combined effect on T-cell output than either alone; no dose change is required, and zinc deficiency is corrected first.
  • Vitamin D: Additive, direction uncertain. High-dose vitamin D shifts T-cell balance toward regulatory subsets, potentially offsetting the stimulation sought. Consequence is a blunted response; steady intake rather than starting both together keeps the effect attributable.
  • Melatonin and pineal peptide preparations: Additive. The strongest reported mortality effect came from Thymalin combined with a pineal peptide, making this the combination with the most supporting data rather than a hazard requiring separation.

Other interventions:

  • Vaccination: Potentiating and deliberate — related thymic peptides are in trials as vaccine-response enhancers. Consequence is a possibly stronger antibody response but also stronger injection-site reactions; separate injection sites and separate days are used.
  • Thymus regeneration protocols (growth hormone plus metformin): Caution. Overlapping intent, unknown combined effect, and consequence is an uninterpretable result rather than a documented harm. Sequential rather than simultaneous use keeps attribution possible.

Populations who should avoid Thymalin:

  • Pregnant or breastfeeding women — listed as a contraindication in the product information, with no reproductive toxicity data available
  • Solid-organ or bone-marrow transplant recipients on any maintenance immunosuppression, at any time post-transplant
  • People with active autoimmune disease requiring systemic therapy (systemic lupus erythematosus, rheumatoid arthritis, Graves’ disease, multiple sclerosis in relapse)
  • People receiving immune checkpoint inhibitors, or with any prior grade 3 or higher immune-related adverse event
  • People with known hypersensitivity to bovine protein, or a prior reaction to any thymus-derived preparation
  • People with a lymphoid malignancy, including chronic lymphocytic leukaemia and untreated monoclonal gammopathy of undetermined significance (a symptomless abnormal antibody-producing cell clone)
  • Children under 14 years outside the age-banded paediatric doses in the product information
  • People with immunoglobulin E-mediated allergic disease severe enough to require carrying an adrenaline autoinjector

Risk Mitigation Strategies

  • Autoimmunity screen before a first course: antinuclear antibodies, thyroid peroxidase antibodies and thyroid-stimulating hormone at baseline; a positive result argues against proceeding and prevents provoking a latent autoimmune process with T-cell stimulation.
  • Low starting dose within the registered range: 5 mg for a first injection rather than 10–20 mg, with 24 hours of observation, limits the size of any hypersensitivity reaction to an injected foreign bovine protein.
  • Short, widely spaced courses: 5–10 consecutive days, repeated no more than twice yearly, matches every published protocol and limits sensitisation from repeated exposure to bovine peptide.
  • Per-vial verification before use: batch certificate of analysis for identity, sterility and endotoxin, intact tamper seal and documented cold chain; this addresses contamination and misidentification in unregulated supply.
  • Allergy response plan for a new batch: first dose given where antihistamine and adrenaline are available addresses the anaphylaxis risk that any injected foreign protein carries, however rarely.
  • Immunostimulant supplements withheld during a course: stopping echinacea, beta-glucans and mushroom extracts avoids stacking immune activation and keeps any adverse reaction attributable to a single agent.
  • No overlap with deliberate immune suppression: transplant immunosuppressants lose effect and checkpoint inhibitors gain toxicity; strict separation prevents graft rejection and severe immune-related adverse events.

Therapeutic Protocol

  • Standard course: 10 mg of lyophilised powder reconstituted in 1–2 mL of sterile isotonic saline, injected intramuscularly once daily for 5–10 consecutive days. The registered adult range is 5–20 mg daily, 30–100 mg per course.
  • Longevity schedule used by the developers: the same 10-day course repeated once or twice yearly. The reported long-term mortality effect came from annually repeated courses over six years, not from continuous dosing.
  • Competing approach — defined single peptides: practitioners outside Russia generally use thymosin alpha-1 (1.6 mg subcutaneously twice weekly) or the isolated dipeptide Thymogen, accepting a narrower but far better characterised molecule.
  • Who popularised each approach: the extract protocol comes from the St. Petersburg Institute of Bioregulation and Gerontology, which developed and commercialises it. The single-peptide protocol descends from Allan Goldstein’s thymosin work and its licensee SciClone.
  • Best time of day: no body-clock timing requirement is documented and the Soviet trials specified none. Morning injection keeps any injection-site reaction observable through waking hours.
  • Half-life: none published for the mixture. Constituent di- and tripeptides are hydrolysed within minutes, so any lasting effect must outlive plasma exposure by acting on gene expression rather than by occupancy.
  • Single versus split dosing: every published protocol uses one daily injection. No trial has compared split dosing, and near-immediate clearance offers no pharmacological argument for it.
  • Genetic polymorphisms: no pharmacogenetic data exist. Human leukocyte antigen type and FOXN1, the gene driving thymic epithelial maintenance, are the plausible modifiers of dose response, but neither has been tested here.
  • Sex-based differences: none reported. The longevity cohort and the COVID-19 trials enrolled both sexes without sex-stratified analysis, so any difference in dose requirement or response remains unmeasured.
  • Age considerations: the entire human case rests on people over 60, where thymic output is lowest. Below roughly age 40 the targeted deficit barely exists and no benefit has been demonstrated.
  • Baseline biomarkers: response was largest in people starting with low lymphocyte counts and raised inflammatory markers. Those beginning with normal counts and normal C-reactive protein have no documented room to improve.
  • Pre-existing conditions: acute infection, burns and post-surgical states are where effects were largest. Stable autoimmune disease is a stated contraindication in the product information, not an indication.

Discontinuation & Cycling

  • Not a lifelong daily therapy: every published protocol is a short course. No study has administered Thymalin continuously for longer than about two weeks, and no continuous-use safety data exist.
  • No withdrawal effects documented: no rebound immune suppression, dependence or withdrawal syndrome has been reported after stopping, and the product information lists none for any duration of use.
  • No taper required: courses end abruptly in every published protocol. There is no pharmacological basis for tapering a peptide mixture cleared from plasma within minutes.
  • Cycling is the design, not an addition: the long-term data come from courses repeated once or twice yearly. Whether more frequent cycling adds anything, or costs anything, is untested.
  • Rationale for spacing courses: repeated exposure to a foreign bovine protein carries a theoretical sensitisation risk, which argues for the widest interval between courses that preserves any effect.

Sourcing and Quality

  • Regulatory identity: Thymalin is a registered prescription drug in Russia, Ukraine and several neighbouring states, manufactured by Samson-Med and by Cytomed. It holds no approval from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency.
  • What the genuine product is: a sterile lyophilised (freeze-dried) powder of 10 mg calf thymus polypeptides with glycine as the inactive carrier, in a sealed vial, reconstituted with isotonic saline immediately before injection. Anything else is a different product.
  • Third-party testing: the relevant document is a batch certificate of analysis covering identity, sterility and bacterial endotoxin. Grey-market “research” vials are routinely sold without one and are not independently tested for any of the three.
  • Bovine source documentation: because the starting material is calf thymus, the source herd’s country matters. Sourcing from countries classified as negligible risk for bovine spongiform encephalopathy (“mad cow disease”) is the relevant assurance.
  • Oral forms are not the studied product: capsules marketed as thymus peptide bioregulators are a different preparation from the injectable used in every trial cited here, and peptides are digested rather than absorbed intact.
  • No legitimate compounded supply exists in the United States: Thymalin is not on the FDA’s list of bulk substances eligible for pharmacy compounding, so any domestically compounded version is outside the regulated system.

Practical Considerations

  • Time to effect: blood immune and inflammatory markers shifted within the 5–10 day course in the published trials. Any longevity effect is inferred from year-scale follow-up and is not perceptible to the individual taking it.
  • Common pitfalls: buying oral capsules instead of the injectable, reconstituting with the wrong diluent, dosing continuously rather than in courses, and expecting a felt effect where the recorded outcome is a laboratory number.
  • Regulatory status: unapproved in the United States, the United Kingdom and the European Union. Personal importation is not permitted, and any use falls entirely outside a licensed indication in those jurisdictions.
  • Cost and accessibility: a ten-vial pack runs roughly US$50–150 from overseas suppliers, so cost is not the constraint. Legality, cold-chain integrity and product verification are the real access barriers.

Interaction with Foundational Habits

  • Sleep: Indirect and potentiating in both directions. Slow-wave sleep is when lymphocyte counts and growth-hormone pulses peak, and short sleep lowers circulating lymphocytes — the very measure Thymalin targets. No sedating or stimulating effect is reported, so injection timing is unconstrained; chronic sleep restriction would blunt any measurable gain.
  • Nutrition: Indirect and potentiating. Thymic tissue depends on adequate protein and zinc, and zinc deficiency alone causes thymic shrinkage. Because the drug is injected, no food-timing rule applies. In anyone deficient, correcting protein or zinc intake first plausibly matters more than the injection itself.
  • Exercise: Indirect. Prolonged high-intensity endurance sessions transiently suppress lymphocyte function for several hours, which would confound any post-course blood test — immune panels drawn at least 48 hours after hard training avoid this. No evidence indicates that Thymalin either blunts or enhances training adaptation.
  • Stress management: Indirect and potentiating. Cortisol drives thymic involution, and glucocorticoid medication opposes precisely the effect sought. Sustained psychological stress or ongoing steroid therapy is the most plausible explanation for a course producing no measurable change.

Monitoring Protocol & Defining Success

Before a first course, testing establishes whether there is anything to correct and rules out conditions in which immune stimulation is unwise. A complete blood count with differential, T-cell subsets by flow cytometry, high-sensitivity C-reactive protein, fibrinogen and D-dimer describe the starting immune and clotting state. Antinuclear antibodies and thyroid peroxidase antibodies screen for silent autoimmunity, and total immunoglobulin E flags the allergic constitution the product information singles out for caution.

Ongoing testing follows the course structure rather than the calendar. The immune and inflammatory panel is repeated at the end of a 5–10 day course, again at 4–6 weeks to show whether any shift persists, and then every 6–12 months where courses are repeated. Autoimmune markers are rechecked annually, and immediately where joint, skin or thyroid symptoms appear.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Absolute lymphocyte count 1.8–3.0 ×10⁹/L The direct target of the drug Conventional range 1.0–4.0 ×10⁹/L; part of a complete blood count with differential; do not draw during acute infection
Absolute CD4 count 0.6–1.2 ×10⁹/L Helper T-cell reserve, the subset that rose most in trials Laboratory reference 0.54–1.46 ×10⁹/L; CD4 is a surface marker on helper T cells; falls with age
CD4/CD8 ratio 1.5–2.5 Balance between helper and cytotoxic T cells Conventional 1.0–3.5; CD8 marks cytotoxic T cells; measured by flow cytometry, a laser method that counts cell types
High-sensitivity C-reactive protein Below 0.5 mg/L General inflammatory load hs-CRP for short; conventional cut-off below 3.0 mg/L; invalid within two weeks of infection, injury or hard exercise
Interleukin-6 Below 2 pg/mL The cytokine that moved most consistently in the trials Conventional below 7 pg/mL; fasting morning draw; costly and not offered by all laboratories
Fibrinogen 200–300 mg/dL Clotting and inflammation, both reported to shift Conventional 200–400 mg/dL; best paired with D-dimer on the same draw
D-dimer Below 0.25 µg/mL fibrinogen-equivalent units Clot formation and breakdown turnover Conventional cut-off below 0.50; rises with age independently of disease; fasting not required
Ferritin 50–150 ng/mL Iron status and an inflammation marker that fell in the trials Conventional 21.8–274.7 ng/mL; an acute-phase protein, so interpret alongside hs-CRP
Antinuclear antibodies Negative, titre below 1:40 Screens for silent autoimmunity before stimulating T cells ANA for short; conventional positive threshold 1:80; low-titre positives are common and non-specific
Thyroid peroxidase antibodies Below 9 IU/mL Thyroid autoimmunity is the type most likely to surface under immune stimulation TPO for short; pair with thyroid-stimulating hormone (TSH); fasting not required
Total immunoglobulin E Below 60 IU/mL The allergic constitution the product information singles out IgE for short; conventional below 100 IU/mL; varies seasonally in allergy-prone people
Erythrocyte sedimentation rate Below 15 mm/h (men), below 20 mm/h (women) Inexpensive non-specific inflammation index that fell in the trials ESR for short; conventional 2–30 mm/h; rises with age and with anaemia

Qualitative markers worth tracking alongside the laboratory panel:

  • Frequency and duration of upper respiratory infections across a full season compared with the previous year
  • Time to recover from a minor infection or a skin wound
  • Daytime energy and exercise tolerance, recorded consistently rather than recalled
  • New or worsening joint pain, morning stiffness, rash or unexplained fatigue — the pattern that would signal an autoimmune reaction
  • Local reaction at the injection site: redness, itching or induration (a hardened, thickened patch of skin), and whether it grows with successive courses

Emerging Research

  • No registered trial of Thymalin exists: A ClinicalTrials.gov search returned no study of Thymalin under any spelling. Every registry entry in this space uses defined single peptides, so the extract’s evidence base is unlikely to grow through Western registration channels.
  • Whether thymic peptides improve vaccine response in older adults: NCT06821100 is a randomised open-label Phase 1 trial of thymosin alpha-1 in 75 adults aged 65 and over receiving a COVID-19 booster, with treatment-emergent adverse events as the primary endpoint and neutralising antibody levels secondary.
  • Whether they change hard cancer outcomes: NCT05086614 is a Phase 3 trial in 2,500 patients after resection of high-risk stage II and III colorectal cancer, with 3-year disease-free survival as the primary endpoint — the scale Thymalin’s own literature has never reached.
  • Identifying what is actually active: Linkova et al., 2023 traced the anti-inflammatory effect to two dipeptides binding gene promoter regions. If confirmed, the extract becomes replaceable by defined molecules, and the case for using the extract itself weakens rather than strengthens.
  • What could overturn the mortality claim: The Cochrane review of Wolf et al., 2011 found no survival benefit for purified thymus extracts in cancer. An independent blinded replication of the 266-person cohort would establish whether the survival signal was real or an artefact of unconcealed allocation.
  • What could strengthen it: Khavinson et al., 2021 produced the only randomised controlled data on Thymalin. A larger blinded trial with a hard endpoint in older adults, run outside the developing institute, would test the longevity claim on its own terms.

Conclusion

Thymalin is a calf thymus extract rather than a defined molecule, and that single fact shapes everything about its evidence. Its proposed job is to restore the supply of immune cells that the shrinking thymus stops producing with age, and laboratory work fits that story: it pushes immature blood-forming cells toward mature immune cells and quiets inflammatory signalling.

The human record is lopsided. Four decades of hospital use in the former Soviet Union produced many reports of faster recovery from burns, surgery, severe infection and radiation injury, and one long follow-up of adults past 60 — the group in whom thymus output is lowest — reported both fewer age-related illnesses and lower death rates. Almost all of it was generated by the institute that developed the compound and by the commercial line built around it, was carried out without concealing who received the drug, and has never been repeated by anyone else. When the studies of related, better-defined thymus peptides are added together, they show a genuine drop in serious infections but no gain in survival, which sits awkwardly beside the survival claim.

Recorded harms are limited and mostly allergic, though the same reporting weakness that inflates the benefit claims means harms could equally be undercounted. The practical obstacles weigh as heavily as the biology: no approval outside a few countries, no verified supply, and an injected foreign protein of uncertain composition. The mechanism is plausible; the evidence that it works in people is thin and, so far, unrepeated.

Top - Benefits - Risks - Protocol